420:(Xolair). The Changs took it to the court in 1993 and accused Genentech of misappropriating its work, but the legal battle dragged on. Chang was granted patents in 1995. In 1996, Tanox and Genentech settled out of court, with Genentech paying Tanox a compensation. The two companies and Novartis agreed to jointly develop Xolair, under the reasoning that Genentech had better manufacturing processes to produce antibodies in large quantities. Chang not only proposed the theory behind anti-IgE therapeutics, but also actively participated in the phase I and II
1343:
1324:
453:
to the bank's claim for a sum of $ 1.7 million. While successful in his claim at the High Court, the decision was reversed on appeal, where the
Singapore Court of Appeal stated that he had the requisite knowledge of shares to not rely on the advice of the bank. He also had to repay a $ 1.7 million debt incurred from investment losses. This case has since become a point of authority in contract law.
1080:
452:
Chang tried his hand at investing, purchasing large quantities of derivatives under
Deutsche Bank's advice. Unfortunately, his scientific expertise did not translate into financial acumen, and as a result he lost $ 50 million in total. Chang initiated a counter-claim for the amount lost in response
332:
therapeutics in 1987. IgE plays a central role in the initiation of hypersensitivity reactions in the human body, and is responsible for allergic diseases that affect 20–40% of the population in developed countries. Originating from Chang's research, antibodies that target the IgE-mediated allergic
361:. In 1993, Chang's patent was granted for his discovery of CεmX, a unique region on human membrane-bound IgE (mIgE), leading to another therapeutic approach to treating IgE-mediated diseases. Apart from anti-IgE therapeutics, Chang also first proposed the concept and methodology of the
431:
for peanut allergy, and obtained very positive results. Genentech, however, sued Tanox, arguing that their contract in 1996 should prevent Tanox from developing any potential competitor drugs to Xolair. Again, the dispute rose to the court. Although Tanox won the consent in a
393:, Inc., where he served as Vice President of Research & Development (1986–1996) and director of the board from 1986 until Tanox was acquired by Genentech in 2007. In order to secure funding for a start-up company based on family funds, the Changs sought collaboration with
1341:, "Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils", published 1995-06-27, assigned to Tanox Biosystems, Inc.
1556:
1447:
Racine-Poon, A.; Botta, L.; Chang, T.W. (1997). "Clinical efficacy of CGP 51901, an anti-IgE chimeric monoclonal antibody, in patients with allergic rhinitis: is it related to the extent of IgE suppression and pharmacokinetics".
287:. Chang's mother, Yeh Ting-mei (葉丁妹), was an elementary school teacher, who worked as a housewife after marriage to raise five children. Chang obtained a bachelor's degree (1970) and master's degree (1972) in chemistry at the
246:
in Taiwan and served as the Dean (1996–1999) of the
College of Life Sciences. Chang was appointed by the Taiwanese government as President of the Development Center for Biotechnology (DCB) in 2000, and served as a
1322:, "Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils", published 1995-06-06, assigned to Tanox Biosystems, Inc.
1564:
1078:, Chang, Tse Wen, "Newly identified human epsilon immunoglobulin peptides and related products", published 1993-12-28, assigned to Tanox Biosystems, Inc.
527:
Detection of antibodies to human T-cell lymphotropic virus-III (HTLV-III) with an immunoassay employing a recombinant
Escherichia coli-derived viral antigenic peptide
427:
Meanwhile, after the settlement in 1996, Tanox continued to develop
Talizumab, not for allergic asthma but for peanut allergy. In 2001–2003, Talizumab entered
1094:
Chan, Yueh-Hsuan; Lee, Yu-Tzu; Chou, Hung-Wen; Wu, Pheidias C.; Chen, Jiun-Bo; Li, Chau-Hong; Cheng, Tien-Tien; Chen, Nien-Yi; Lue, Ko-Haung (2014-05-01).
1762:
1392:"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics"
476:
463:
416:
A few years later, legal disputes arose as the Changs discovered that
Genentech launched its own anti-IgE program, developing what now became known as
333:
pathway have proven effective in the treatment of various allergic diseases. Among these anti-IgE drugs are: Omalizumab (Xolair), approved by the U.S.
1656:
766:
1290:
648:
583:
1727:
248:
397:
in 1989, sending data and samples of early anti-IgE antibody, but talks with
Genentech were unsuccessful. In 1990, Tanox partnered with
365:
in 1983. By aligning antibodies of distinct specificities in a matrix-like manner, scientists are able to detect and quantify multiple
1493:
1450:
788:
1390:
Corne, J.; Djukanovic, R.; Thomas, L.; Warner, J.; Botta, L.; Grandordy, B.; Gygax, D.; Heusser, C.; Patalano, F. (1997-03-01).
850:
1752:
1195:
1025:
312:
1599:
Jayaraman, K. S.; Louët, Sabine; Powell, Kendall; Ransom, John; Sheridan, Cormac; Vastag, Brian; Waltz, Emily (2006-03-01).
1358:
540:
Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-medicated allergic diseases
1557:"Deutsche Bank AG v Chang Tse Wen and another appeal. [2013] SGCA 49. Civil Appeals Nos 164 of 2012 and 2 of 2013"
1732:
1096:"Developing an antibody targeting CϵmX of mIgE for the treatment of allergic and other IgE-mediated diseases (VAC6P.954)"
1742:
255:
from 2002 to 2006. From 2006 to 2016, he was tenured as
Distinguished Research Fellow at the Genomics Research Center,
618:
Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells
1747:
1514:
1722:
891:"Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations"
719:"Tanox, Inc. – Company Profile, Information, Business Description, History, Background Information on Tanox, Inc"
669:
Chang, Tse Wen; Chen, Christina; Lin, Chien-Jen; Metz, Martin; Church, Martin K.; Maurer, Marcus (2015-02-01).
631:
Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations
500:
284:
182:
482:
338:
288:
243:
220:
143:
70:
436:, it lost the arbitration that followed, and the development of Talizumab for peanut allergy was suspended.
334:
1141:
Chang, T. W. (1983-12-16). "Binding of cells to matrixes of distinct antibodies coated on solid surface".
889:
Chu, Hsing-Mao; Wright, Jon; Chan, Yueh-Hsuan; Lin, Chien-Jen; Chang, Tse Wen; Lim, Carmay (2014-01-24).
472:'s shortlist of personalities who made the most significant contribution to biotech in the past 10 years.
518:
1298:
877:
671:"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria"
643:
602:
591:
578:
1008:
Leung DY, Shanahan WR, Li XM, Sampson HA (2004). "New approaches for the treatment of anaphylaxis".
1268:
644:
The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria
428:
1535:
1211:
1757:
744:
718:
565:
526:
525:
Chang TW, Kato I, McKinney S, Chanda P, Barone AD, Wong-Staal F, Gallo RC, and Chang NT, 1985, "
1737:
539:
433:
272:
58:
1677:
1578:
946:
635:
622:
557:
369:
in one simultaneous attempt. Thereafter, many other types of microarrays emerged, including
1717:
902:
570:
544:
531:
514:
Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?
469:
1095:
1012:. Novartis Foundation Symposia. Vol. 257. pp. 248–60, discussion 260–4, 276–85.
8:
810:
362:
296:
108:
906:
1633:
1600:
1475:
1123:
700:
374:
300:
292:
280:
166:
83:
1463:
1424:
1391:
603:
Cumulative environmental changes, skewed antigen exposure, and the increase of allergy
199:, born August 25, 1947) is a Taiwanese immunologist. His early research involving the
1638:
1620:
1467:
1429:
1411:
1366:
1244:
1191:
1166:
1158:
1154:
1115:
1111:
1031:
1021:
987:
928:
920:
861:
692:
346:
1479:
1236:
1127:
704:
1628:
1612:
1459:
1419:
1403:
1150:
1107:
1013:
977:
969:
910:
682:
617:
504:
329:
276:
268:
228:
200:
161:
103:
54:
1049:
1185:
613:
256:
152:
538:
Chang TW, Davis FM, Sun NC, Sun CRY, MacGlashan Jr. DW, and
Hamilton RG, 1990, "
283:, China. His father Chang Chun-an (張均安) spent his entire career working for the
687:
670:
421:
386:
370:
350:
252:
1494:"Genentech, Novartis and Tanox Settle Disputes Surrounding Xolair and TNX-901"
513:
398:
1711:
1624:
1415:
1370:
1248:
1162:
1119:
924:
630:
133:
1017:
552:
215:), a medication that has been approved for the treatment of severe allergic
1642:
1075:
1035:
991:
932:
696:
308:
1471:
1433:
1338:
1319:
1170:
402:
1291:"Drug war. (small drug firm Tanox takes on Genentech over patent rights)"
982:
964:
354:
129:
1616:
832:
915:
890:
592:
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
486:
417:
208:
125:
1407:
410:
394:
342:
303:. Chang received his Ph.D. in 1977, and did postdoctoral research on
235:
406:
358:
239:
204:
551:
Peng C, Davis FM, Sun LK, Liou RS, Kim Y-W, and Chang TW, 1992, "
366:
1581:(in Chinese (Taiwan)). Genomics Research Center, Academia Sinica
629:
Chu HM, Wright J, Chan YH, Lin CJ, Chang TW & Lim C, 2014, "
357:, a high-affinity TNX-901 under active clinical development at
304:
216:
212:
190:
98:
642:
Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M, 2015, "
501:
Selection pressure of homologous proteins of varied activities
390:
224:
147:
78:
74:
965:"Effect of anti-IgE therapy in patients with peanut allergy"
838:. The Taiwan Society for Biochemistry and Molecular Biology.
1389:
464:
American
College of Allergy, Asthma, and Immunology (ACAAI)
1659:. The American Academy of Allergy, Asthma & Immunology
1598:
1184:
Abu-Jamous, Basel; Fa, Rui; Nandi, Asoke K. (2015-04-16).
87:
1701:
963:
Leung DY, Sampson HA, Yunginger JW, et al. (2003).
444:
In 2014, Chang started the company Immunwork in Taiwan.
242:
was made in 1996, Chang returned to his alma mater, the
512:
Chang TW, Kung PC, Gingras SP, and Goldstein G, 1981, "
291:. Afterwards, Chang received a four-year fellowship at
1007:
1446:
962:
579:
Anti-IgE as a mast cell-stabilizing therapeutic agent
477:
American Academy of Allergy, Asthma, and Immunology
231:therapies for the treatment of allergic diseases.
1237:"How Genentech, Novartis Stifled A Promising Drug"
227:, a biopharmaceutical company specialized in anti-
1704:", Biotech company founded and directed by Chang.
1183:
769:. Board of Science and Technology, Executive Yuan
612:Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM,
1709:
888:
668:
1003:
1001:
958:
956:
337:(FDA) for the treatment of allergic asthma and
323:
207:-based therapeutics lead to the development of
1187:Integrative Cluster Analysis in Bioinformatics
649:The Journal of Allergy and Clinical Immunology
584:The Journal of Allergy and Clinical Immunology
275:, Taiwan in 1947. His ancestry traces back to
1093:
566:The pharmacological basis of anti-IgE therapy
345:(TNX-901), shown to be effective in treating
29:
998:
953:
791:. Genomics Research Center, Academia Sinica
1763:Taiwanese expatriates in the United States
675:Journal of Allergy and Clinical Immunology
234:After Tanox's tripartite partnership with
1632:
1423:
1359:"Wrangling May Delay Peanut Allergy Drug"
981:
914:
686:
590:Chang TW, Wu PC, Hsu CL, Hung AF, 2007, "
553:A new isoform of human membrane-bound IgE
311:at the Center for Cancer Research at the
1451:Clinical Pharmacology & Therapeutics
1234:
493:
380:
1356:
1710:
1657:"Past AAAAI Honorary Award Recipients"
1288:
259:. He founded Immunwork, Inc. in 2014.
1396:The Journal of Clinical Investigation
1230:
1228:
1190:. John Wiley & Sons. p. 56.
1140:
1074:
447:
313:Massachusetts Institute of Technology
1728:National Tsing Hua University alumni
456:
1678:"TWAS announces 2014 Prize winners"
1563:. 19 September 2013. Archived from
341:(primarily an autoimmune disease);
13:
1225:
299:in the muscle during fasting with
295:, where he did thesis research on
16:Taiwanese immunologist (born 1947)
14:
1774:
1694:
1235:Hamilton, David P. (2005-04-05).
949:. Drugdevelopment-technology.com.
848:
830:
1143:Journal of Immunological Methods
1112:10.4049/jimmunol.192.Supp.140.15
424:of Talizumab from 1990 to 1996.
1670:
1649:
1592:
1571:
1549:
1528:
1515:"Five Questions with Immunwork"
1507:
1486:
1440:
1383:
1350:
1331:
1312:
1289:Thorpe, Helen (April 1, 1995).
1282:
1261:
1204:
1177:
1134:
1087:
1068:
1042:
939:
747:. National Tsing Hua University
577:Chang TW and Shiung YY, 2006, "
462:Honorary Fellow Award from the
1357:Pollack, Andrew (2003-03-13).
882:
842:
824:
803:
781:
759:
737:
711:
662:
195:
186:
30:
1:
1517:(Blog). Terrapinn. 2016-09-23
1464:10.1016/S0009-9236(97)90087-4
947:"Xolair – Biological Therapy"
656:
483:The World Academy of Sciences
439:
339:chronic spontaneous urticaria
289:National Tsing Hua University
267:Chang was born and raised in
244:National Tsing Hua University
221:chronic spontaneous urticaria
144:National Tsing Hua University
71:National Tsing Hua University
1753:People from Zhongli District
1155:10.1016/0022-1759(83)90318-6
601:Chang TW and Pan AY, 2008, "
335:Food and Drug Administration
324:Contributions to biomedicine
262:
7:
1269:"Sample Business Contracts"
475:Honorary Fellow Award from
385:In March 1986, Tse Wen and
10:
1779:
1733:Taiwanese biotechnologists
1496:(Press release). Genentech
688:10.1016/j.jaci.2014.04.036
519:Proc. Natl. Acad. Sci. USA
489:in Medical Sciences, 2014.
223:. Chang is a cofounder of
1743:Harvard University alumni
1100:The Journal of Immunology
767:"張子文 (Dr. Tse-Wen Chang)"
499:Chang TW, Tang N, 1972, "
409:) and started developing
401:(which later merged with
318:
315:(MIT) from 1977 to 1980.
172:
160:
139:
121:
114:
94:
66:
37:
28:
21:
1748:People from Taoyuan City
1106:(1 Supplement): 140.15.
849:龐, 中培 (September 2005).
429:phase II clinical trials
1723:Taiwanese immunologists
1018:10.1002/0470861193.ch20
307:immune mechanisms with
1601:"Who's who in biotech"
1271:. contracts.onecle.com
723:Reference for Business
607:Advances in Immunology
596:Advances in Immunology
434:federal district court
285:Taiwan Railroad Bureau
249:Science and Technology
1339:U.S. Patent 5428133 A
1320:U.S. Patent 5422258 A
1076:U.S. Patent 5274075 A
895:Nature Communications
652:, 135(2), 337–342.e2.
636:Nature Communications
623:Journal of Immunology
558:Journal of Immunology
494:Selected publications
381:Work in biotechnology
1605:Nature Biotechnology
1579:"Chang, Tse Wen 張子文"
983:10.1056/NEJMoa022613
831:張, 子文 (2017-03-23).
813:. Harvard University
626:, 184(4), 1748–1756.
587:, 117(6), 1203–1212.
571:Nature Biotechnology
545:Nature Biotechnology
532:Nature Biotechnology
470:Nature Biotechnology
328:Chang invented anti-
1617:10.1038/nbt0306-291
1561:www.singaporelaw.sg
1301:on October 29, 2013
1241:Wall Street Journal
907:2014NatCo...5.3139C
858:Scientific American
616:, Chang TW, 2010, "
375:protein microarrays
297:protein degradation
109:Antibody microarray
1567:on 14 August 2018.
1363:The New York Times
916:10.1038/ncomms4139
851:"從抗體到藥物──專訪 張子文教授"
833:"走上新藥研究與事業新創的心路歷程"
448:Investing attempts
301:Alfred L. Goldberg
293:Harvard University
281:Guangdong Province
203:(IgE) pathway and
167:Alfred L. Goldberg
84:Harvard University
1408:10.1172/JCI119252
1197:978-1-118-90655-2
1027:978-0-470-86119-6
811:"Alfred Goldberg"
681:(2): 337–342.e2.
574:, 18(2), 157–162.
564:Chang TW, 2000, "
457:Awards and honors
347:allergic rhinitis
176:
175:
116:Scientific career
1770:
1689:
1688:
1686:
1685:
1674:
1668:
1667:
1665:
1664:
1653:
1647:
1646:
1636:
1596:
1590:
1589:
1587:
1586:
1575:
1569:
1568:
1553:
1547:
1546:
1544:
1543:
1532:
1526:
1525:
1523:
1522:
1511:
1505:
1504:
1502:
1501:
1490:
1484:
1483:
1444:
1438:
1437:
1427:
1387:
1381:
1380:
1378:
1377:
1354:
1348:
1347:
1346:
1342:
1335:
1329:
1328:
1327:
1323:
1316:
1310:
1309:
1307:
1306:
1297:. Archived from
1286:
1280:
1279:
1277:
1276:
1265:
1259:
1258:
1256:
1255:
1232:
1223:
1222:
1220:
1219:
1208:
1202:
1201:
1181:
1175:
1174:
1149:(1–2): 217–223.
1138:
1132:
1131:
1091:
1085:
1084:
1083:
1079:
1072:
1066:
1065:
1063:
1061:
1046:
1040:
1039:
1005:
996:
995:
985:
970:N. Engl. J. Med.
960:
951:
950:
943:
937:
936:
918:
886:
880:
876:
874:
872:
867:on July 15, 2020
866:
860:. Archived from
855:
846:
840:
839:
837:
828:
822:
821:
819:
818:
807:
801:
800:
798:
796:
789:"Chang, Tse Wen"
785:
779:
778:
776:
774:
763:
757:
756:
754:
752:
741:
735:
734:
732:
730:
715:
709:
708:
690:
666:
522:, 78, 1805–1808.
377:, among others.
349:(hay fever) and
269:Zhongli District
201:Immunoglobulin E
197:
188:
162:Doctoral advisor
55:Zhongli District
51:
47:
45:
33:
32:
19:
18:
1778:
1777:
1773:
1772:
1771:
1769:
1768:
1767:
1708:
1707:
1697:
1692:
1683:
1681:
1676:
1675:
1671:
1662:
1660:
1655:
1654:
1650:
1597:
1593:
1584:
1582:
1577:
1576:
1572:
1555:
1554:
1550:
1541:
1539:
1534:
1533:
1529:
1520:
1518:
1513:
1512:
1508:
1499:
1497:
1492:
1491:
1487:
1445:
1441:
1388:
1384:
1375:
1373:
1355:
1351:
1344:
1337:
1336:
1332:
1325:
1318:
1317:
1313:
1304:
1302:
1287:
1283:
1274:
1272:
1267:
1266:
1262:
1253:
1251:
1233:
1226:
1217:
1215:
1210:
1209:
1205:
1198:
1182:
1178:
1139:
1135:
1092:
1088:
1081:
1073:
1069:
1059:
1057:
1048:
1047:
1043:
1028:
1006:
999:
961:
954:
945:
944:
940:
887:
883:
870:
868:
864:
853:
847:
843:
835:
829:
825:
816:
814:
809:
808:
804:
794:
792:
787:
786:
782:
772:
770:
765:
764:
760:
750:
748:
743:
742:
738:
728:
726:
717:
716:
712:
667:
663:
659:
561:, 148, 129–136.
496:
459:
450:
442:
422:clinical trials
383:
371:DNA microarrays
363:antibody matrix
326:
321:
265:
257:Academia Sinica
251:Advisor of the
211:(also known as
156:Immunwork, Inc.
155:
153:Academia Sinica
151:
146:
107:
101:
82:
62:
52:
49:
48:August 25, 1947
43:
41:
24:
17:
12:
11:
5:
1776:
1766:
1765:
1760:
1758:TWAS laureates
1755:
1750:
1745:
1740:
1735:
1730:
1725:
1720:
1706:
1705:
1696:
1695:External links
1693:
1691:
1690:
1669:
1648:
1611:(3): 291–300.
1591:
1570:
1548:
1527:
1506:
1485:
1439:
1402:(5): 879–887.
1382:
1349:
1330:
1311:
1281:
1260:
1224:
1203:
1196:
1176:
1133:
1086:
1067:
1041:
1026:
997:
976:(11): 986–93.
952:
938:
881:
841:
823:
802:
780:
758:
736:
725:. Advameg, Inc
710:
660:
658:
655:
654:
653:
640:
627:
610:
599:
588:
575:
562:
549:
536:
523:
510:
495:
492:
491:
490:
480:
479:(AAAAI), 2007.
473:
467:
458:
455:
449:
446:
441:
438:
387:Nancy T. Chang
382:
379:
351:peanut allergy
325:
322:
320:
317:
273:Taoyuan County
264:
261:
253:Executive Yuan
174:
173:
170:
169:
164:
158:
157:
141:
137:
136:
123:
119:
118:
112:
111:
96:
95:Known for
92:
91:
68:
64:
63:
59:Taoyuan County
53:
39:
35:
34:
26:
25:
22:
15:
9:
6:
4:
3:
2:
1775:
1764:
1761:
1759:
1756:
1754:
1751:
1749:
1746:
1744:
1741:
1739:
1738:Living people
1736:
1734:
1731:
1729:
1726:
1724:
1721:
1719:
1716:
1715:
1713:
1703:
1699:
1698:
1679:
1673:
1658:
1652:
1644:
1640:
1635:
1630:
1626:
1622:
1618:
1614:
1610:
1606:
1602:
1595:
1580:
1574:
1566:
1562:
1558:
1552:
1537:
1531:
1516:
1510:
1495:
1489:
1481:
1477:
1473:
1469:
1465:
1461:
1458:(6): 675–90.
1457:
1453:
1452:
1443:
1435:
1431:
1426:
1421:
1417:
1413:
1409:
1405:
1401:
1397:
1393:
1386:
1372:
1368:
1364:
1360:
1353:
1340:
1334:
1321:
1315:
1300:
1296:
1295:Texas Monthly
1292:
1285:
1270:
1264:
1250:
1246:
1242:
1238:
1231:
1229:
1213:
1212:"Our Founder"
1207:
1199:
1193:
1189:
1188:
1180:
1172:
1168:
1164:
1160:
1156:
1152:
1148:
1144:
1137:
1129:
1125:
1121:
1117:
1113:
1109:
1105:
1101:
1097:
1090:
1077:
1071:
1056:. May 4, 2017
1055:
1051:
1050:"Ligelizumab"
1045:
1037:
1033:
1029:
1023:
1019:
1015:
1011:
1004:
1002:
993:
989:
984:
979:
975:
972:
971:
966:
959:
957:
948:
942:
934:
930:
926:
922:
917:
912:
908:
904:
900:
896:
892:
885:
879:
863:
859:
852:
845:
834:
827:
812:
806:
790:
784:
768:
762:
746:
745:"2008年：張子文校友"
740:
724:
720:
714:
706:
702:
698:
694:
689:
684:
680:
676:
672:
665:
661:
651:
650:
645:
641:
638:
637:
632:
628:
625:
624:
619:
615:
611:
608:
604:
600:
598:, 93, 63–119.
597:
593:
589:
586:
585:
580:
576:
573:
572:
567:
563:
560:
559:
554:
550:
548:, 8, 122–126.
547:
546:
541:
537:
535:, 3, 905–909.
534:
533:
528:
524:
521:
520:
515:
511:
508:
507:
502:
498:
497:
488:
484:
481:
478:
474:
471:
468:
465:
461:
460:
454:
445:
437:
435:
430:
425:
423:
419:
414:
412:
408:
404:
400:
396:
392:
388:
378:
376:
372:
368:
364:
360:
356:
352:
348:
344:
340:
336:
331:
316:
314:
310:
306:
302:
298:
294:
290:
286:
282:
278:
274:
270:
260:
258:
254:
250:
245:
241:
237:
232:
230:
226:
222:
218:
214:
210:
206:
202:
198:
192:
184:
180:
179:Tse Wen Chang
171:
168:
165:
163:
159:
154:
149:
145:
142:
138:
135:
134:Biotechnology
131:
127:
124:
120:
117:
113:
110:
105:
100:
97:
93:
89:
85:
80:
76:
72:
69:
65:
60:
56:
50:(age 77)
40:
36:
27:
23:Tse Wen Chang
20:
1682:. Retrieved
1672:
1661:. Retrieved
1651:
1608:
1604:
1594:
1583:. Retrieved
1573:
1565:the original
1560:
1551:
1540:. Retrieved
1530:
1519:. Retrieved
1509:
1498:. Retrieved
1488:
1455:
1449:
1442:
1399:
1395:
1385:
1374:. Retrieved
1362:
1352:
1333:
1314:
1303:. Retrieved
1299:the original
1294:
1284:
1273:. Retrieved
1263:
1252:. Retrieved
1240:
1216:. Retrieved
1206:
1186:
1179:
1146:
1142:
1136:
1103:
1099:
1089:
1070:
1058:. Retrieved
1054:Adis Insight
1053:
1044:
1009:
973:
968:
941:
898:
894:
884:
869:. Retrieved
862:the original
857:
844:
826:
815:. Retrieved
805:
793:. Retrieved
783:
771:. Retrieved
761:
749:. Retrieved
739:
727:. Retrieved
722:
713:
678:
674:
664:
647:
634:
621:
609:, 98, 39–83.
606:
595:
582:
569:
556:
543:
530:
517:
505:
451:
443:
426:
415:
384:
327:
309:Herman Eisen
266:
233:
194:
178:
177:
140:Institutions
115:
1718:1947 births
1538:. Immunwork
1214:. Immunwork
1010:Anaphylaxis
509:, 239, 207.
413:(TNX-901).
355:Ligelizumab
219:and severe
196:Zhāng Zǐwén
130:Biomedicine
1712:Categories
1684:2017-05-26
1663:2017-05-26
1585:2017-05-26
1542:2017-05-26
1536:"Overview"
1521:2017-05-26
1500:2017-06-15
1376:2017-05-26
1305:2017-06-15
1275:2017-05-16
1254:2017-05-16
1218:2017-05-16
817:2017-06-13
657:References
639:, 5, 3139.
440:Post-Tanox
418:Omalizumab
399:Ciba-Geigy
277:Mei County
209:omalizumab
126:Immunology
44:1947-08-25
1702:Immunwork
1625:1087-0156
1416:0021-9738
1371:0362-4331
1249:0099-9660
1163:0022-1759
1120:0022-1767
925:2041-1723
411:Talizumab
395:Genentech
343:Talizumab
263:Education
236:Genentech
67:Education
1643:16525392
1480:28652703
1128:82305273
1036:15025403
992:12637608
933:24457896
901:: 3139.
705:13090739
697:24948369
614:Chang HY
407:Novartis
405:to form
389:founded
367:antigens
359:Novartis
240:Novartis
205:antibody
61:, Taiwan
1634:7097553
1472:9433396
1434:9062345
1171:6606681
903:Bibcode
878:Alt URL
485:(TWAS)
466:, 2004.
183:Chinese
106:therapy
1680:. TWAS
1641:
1631:
1623:
1478:
1470:
1432:
1425:507895
1422:
1414:
1369:
1345:
1326:
1247:
1194:
1169:
1161:
1126:
1118:
1082:
1060:15 May
1034:
1024:
990:
931:
923:
871:15 May
703:
695:
506:Nature
403:Sandoz
353:; and
319:Career
305:T cell
217:asthma
213:Xolair
193::
191:pinyin
185::
150:, Inc.
122:Fields
99:Xolair
1476:S2CID
1124:S2CID
865:(PDF)
854:(PDF)
836:(PDF)
795:3 May
773:3 May
751:3 May
729:3 May
701:S2CID
487:Prize
391:Tanox
225:Tanox
148:Tanox
102:anti-
1639:PMID
1621:ISSN
1468:PMID
1430:PMID
1412:ISSN
1367:ISSN
1245:ISSN
1192:ISBN
1167:PMID
1159:ISSN
1116:ISSN
1062:2017
1032:PMID
1022:ISBN
988:PMID
929:PMID
921:ISSN
873:2017
797:2017
775:2017
753:2017
731:2017
693:PMID
373:and
238:and
38:Born
1629:PMC
1613:doi
1460:doi
1420:PMC
1404:doi
1151:doi
1108:doi
1104:192
1014:doi
978:doi
974:348
911:doi
683:doi
679:135
646:."
633:."
620:."
605:."
594:."
581:."
568:."
555:."
542:."
529:."
503:."
330:IgE
229:IgE
187:張子文
104:IgE
88:PhD
31:張子文
1714::
1637:.
1627:.
1619:.
1609:24
1607:.
1603:.
1559:.
1474:.
1466:.
1456:62
1454:.
1428:.
1418:.
1410:.
1400:99
1398:.
1394:.
1365:.
1361:.
1293:.
1243:.
1239:.
1227:^
1165:.
1157:.
1147:65
1145:.
1122:.
1114:.
1102:.
1098:.
1052:.
1030:.
1020:.
1000:^
986:.
967:.
955:^
927:.
919:.
909:.
897:.
893:.
856:.
721:.
699:.
691:.
677:.
673:.
516:"
279:,
271:,
189:;
132:,
128:,
79:MS
77:,
75:BS
57:,
46:)
1700:"
1687:.
1666:.
1645:.
1615::
1588:.
1545:.
1524:.
1503:.
1482:.
1462::
1436:.
1406::
1379:.
1308:.
1278:.
1257:.
1221:.
1200:.
1173:.
1153::
1130:.
1110::
1064:.
1038:.
1016::
994:.
980::
935:.
913::
905::
899:5
875:.
820:.
799:.
777:.
755:.
733:.
707:.
685::
181:(
90:)
86:(
81:)
73:(
42:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.